Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 1,061 | 986 | 2,681 | 3,239 | 6,886 |
Gross Profit | 1,061 | 986 | 2,681 | 3,239 | 6,886 |
Operating Expenses | 27,475 | 23,032 | 28,678 | 22,310 | 26,027 |
Operating Income | -26,414 | -22,046 | -25,997 | -19,071 | -19,141 |
Other Income | 31,664 | -12,793 | -1,925 | 1,059 | 1,107 |
Pre-tax Income | 5,250 | -34,839 | -27,922 | -18,012 | -18,034 |
Income Tax | 189 | 24 | -30 | 29 | 757 |
Net Income Continuous | 5,061 | -34,863 | -27,892 | -18,041 | -18,791 |
Net Income | $5,061 | $-34,863 | $-27,892 | $-18,041 | $-18,791 |
EPS Basic Total Ops | 0.75 | -5.50 | 0.25 | -10.25 | -10.75 |
EPS Basic Continuous Ops | 0.81 | -5.58 | 0.50 | -10.37 | -10.87 |
EPS Diluted Total Ops | 0.75 | -5.50 | 0.25 | -10.25 | -10.75 |
EPS Diluted Continuous Ops | 0.81 | -5.58 | 0.50 | -10.37 | -10.87 |
EPS Diluted Before Non-Recurring Items | 0.75 | -5.50 | -5.50 | -10.25 | -10.75 |
EBITDA(a) | $-26,656 | $-21,456 | $-25,222 | $-18,390 | $-18,529 |